SecBot SecBot
8-K ·Filed Nov 3, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed13d 11h ago SEC0001819790-26-000074
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The core XDEMVY franchise continues to grow at ~64% YoY with strong refill rates, but the $632M IPRD charge and cash burn from acquisitions will pressure the balance sheet. Monitor the Q3 10-Q for updated cash runway and any guidance on pipeline milestones (TP-04, TP-05, IRX-101, gildeuretinol) expected in 1H 2027.

DirectionNeutral
Confidencehigh
Horizonimmediate

ALK-001

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
Next catalyst
None dated

What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

Price Chart

Loading chart...

Executive Summary

Tarsus Pharmaceuticals reported Q3 2026 XDEMVY net product sales of $194.6 million, up ~64% YoY, surpassing $1 billion in cumulative sales since launch. The reported GAAP net loss of $668.3 million ($14.40 per share) was driven by $632.2 million in acquired in-process R&D expenses from the iRenix and Alkeus acquisitions, masking strong underlying commercial momentum. No guidance was provided in the release.

Key Financial Metrics

EPS
−$14.40
Revenue
$194.6M
est $190.8M · +2.0% · +63.9% YoY
Gross Margin
93%

Key Facts

  • Q3 2026 XDEMVY net product sales of $194.6 million, up ~64% year-over-year from $118.7 million
  • Cumulative net product sales surpassed $1 billion since launch; over one million bottles dispensed
  • GAAP net loss of $668.3 million ($14.40 per share) vs. $12.6 million ($0.30) in Q3 2025, driven by $632.2 million in acquired IPRD expenses
  • Cash, cash equivalents and marketable securities of $309.6 million as of September 30, 2026, down from $449.7 million at June 30, 2026
  • Gross margins remained consistent at approximately 93%
  • Refills accounted for approximately 20% of XDEMVY prescriptions in Q3
  • Appointed Neera Clase as Chief Commercial Officer

Financial Impact

Q3 product sales of $194.6M, up ~64% YoY; GAAP net loss of $668.3M includes $632.2M non-cash IPRD charge; cash position $309.6M

revenuenet losscash position

Risk Factors

  • Large GAAP net loss and IPRD charges obscure underlying profitability
  • Cash and marketable securities declined $140M from Q2 to $309.6M, raising potential need for future capital
  • No updated full-year 2026 guidance was provided in the release

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001819790-26-000074
Document: tars-20261103.htm0001819790-26-000074
Document: 0001819790-26-000074-index-headers.html0001819790-26-000074
Document: 0001819790-26-000074-index.html0001819790-26-000074
Document: 0001819790-26-000074.txt0001819790-26-000074
8-K Data (Synthetic)0001819790-26-000074

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 Viewing No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026